Navigation Links
Alsius Corporation Announces Program for Early Exercise of Warrants
Date:12/18/2007

IRVINE, Calif., Dec. 18 /PRNewswire-FirstCall/ -- Alsius Corporation (Nasdaq: ALUS), which designs, manufactures and sells advanced patient temperature management therapies, announced today that the company has launched offers to holders of all 16,541,000 outstanding, publicly traded warrants, the opportunity, for a limited time, to exercise the warrants on amended terms.

Alsius is modifying the terms of the warrants to allow holders to receive one share of common stock for every 5.5 warrants surrendered, without paying a cash exercise price. In addition, for each 5.5 warrants a holder tenders in the cashless exercise, the holder can exercise one additional warrant by paying a reduced cash exercise price of $3.25 for one share of common stock. Exercising warrants at the reduced cash price is not a requirement to participating in the cashless exercise.

The offer will commence on December 19, 2007, and continue for a period of 20 business days, expiring on January 18, 2008 at 5 p.m., Eastern Standard Time (the "Offer Period") unless extended, terminated or withdrawn. Existing warrants must be tendered prior to the expiration of the offer, and tenders of existing warrant may be withdrawn at anytime on or prior to the expiration of the offer. Withdrawn warrants will be returned to the holder in accordance with the terms of the offer. Upon termination of the offer, the original terms of the warrants will be reinstituted and the warrants will expire on August 16, 2009, unless earlier redeemed according to their original terms.

"The purpose of the offer is primarily to reduce the number of warrants outstanding. The offer will also raise additional capital if holders take advantage of the reduced cash exercise price," said Bi
'/>"/>

SOURCE Alsius Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Alsius Corporation to Host Third Quarter 2007 Financial Results Conference Call/Webcast on November 13, 2007
2. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
3. Brooke Franchise Corporation Announces Selected July Results
4. MedThink Communications Retained by NanoBio Corporation
5. EaglePicher Corporation Completes Transaction to Sell EaglePicher Boron, LLC to Ceradyne, Inc. for $69 Million
6. Dana Corporation, Inc. Enters Into Settlement Agreement With Dana Retiree Committee
7. Memry Corporation Announces Fiscal Fourth Quarter and 2007 Year End Earnings Release and Conference Call
8. Somanetics Corporation to Release Third Quarter 2007 Financial Results and Host Conference Call September 19
9. LifeQuest World Corporation Proud Contributor to Dietary Supplement Education Alliance (DSEA)
10. DTI Medical Corporation Announces Reverse Split and Other Corporate Developments
11. STERIS Corporation Board of Directors Names Walter M. Rosebrough Jr. President and Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)... BOSTON, Nov. 21 Innerscope Resea... firm specializing in Emotional Response Measureme...utives who will strengthen the,company,s research...,initiatives. , The three appointments, who...de Geoffrey Gill as Chief Financial Officer and Vi...
(Date:11/21/2008)... , COLD SPRING HARBOR, N.Y. (Nov. 21, 2008) Ho...What can the lamprey immune system tell us about e...ations help with efforts to conserve rare species?...duction, and hereditary diseases? Will studies of... , To answer these and other questions in biolog...
(Date:11/21/2008)... WASHINGTON, Nov. 21 New inventio... with a variety of cognitive disabilities lead ful...ience(R) Corporation. Zimman,presented today at t...ington,DC, a meeting organized by The National C...tion to assist people with disabilities. , ...
(Date:11/21/2008)... Winter viruses may be to blame, study suggests ...The season of a baby,s birth may help predict that..., Babies born in autumn -- about four months befo...a 30 percent increased risk of asthma compared to ...study in the first December issue of the American...
Breaking Medicine News(10 mins):Health News:Innerscope Research Strengthens Management Team With Three Executive Appointments 2Health News:A new world of research possibilities with 'Emerging Model Organisms' 2Health News:New Applications for Cognitive Training 2Health News:Autumn Babies More Prone to Asthma 2Health News:Autumn Babies More Prone to Asthma 3
...s of vitamin C notwithstanding, British researcher...! It is now said that vitamin C reverses pre eclam...e leading contributors to complications in childbi...n lead onto eclampsia which, when left untreated, ...
...hat causes infectious mononucleosis, Epstein-Barr ...o the development of Hodgkin's disease. But no one...BV and Hodgkin's survival, according to researcher... from Northern California Cancer Center in Union C...
...d on more than 1600 women reveals that parathyroid...ne density and cut the risk of fractures in them. ...ium levels in the body. The new aspect of th...ures has opened up the prospect of the hormone bei...
...n from Mayo Foundation in Rochester, Minnesota has...ble metal stents in the digestive tract of people ...ese patients commonly suffer from obstructions and...ke difficulty in swallowing, if the block is in th...
Other Medicine News:
(Date:11/20/2008)...- The Scandinavian-based drug,development company...on its,lead antimicrobial candidate LTX-109. Pres...wed that the novel lytic peptidomimetic has an ult...er towards killing Staphylococcus,aureus and Stre...gs. In,addition to this it has proven effective a...
(Date:11/19/2008)...significance , , ISELIN, N.J., Nov. 19 /PR...: PARS ) today announced results from its Phase ... drug delivery technology formulated with 3% Diclo... randomized, double-blinded, placebo-controlled st...ny,s 3% Diclofenac Diethanolamine NanoEmulsion cre...
(Date:11/19/2008)...a contract development and,manufacturing organiza...t,phase launch of its contract facility in Delawa...e process, facility and capacity problems commonly...w-volume clinical and,early-stage commercial ster... invest over $100 million and four years to develo...
(Date:11/18/2008)...make a donation or send a Christmas Seals e-card ,...re/ -- Millions will receive Christmas Seals in th...ssociation. These decorative holiday stamps are pa...to 1907 when the Lung Association led efforts to c...alive today have no vivid memories of how widespre...
Breaking Medicine Technology:Lytix Presents LTX-109 Anti-Microbial Data at ICAAC 2Pharmos Announces Clinical Results from Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream 2Isogen Launches Major New Facility to Address Global Biopharma Demand 2American Lung Association Celebrates 101st Annual Christmas Seals Campaign 2Julia Zeitlinger named Pew Scholar 3651 1Julia Zeitlinger named Pew Scholar 3651 2INACSL and Elsevier partner to publish Clinical Simulation in Nursing 21981 1INACSL and Elsevier partner to publish Clinical Simulation in Nursing 21981 2AHIP Statement on American Medical Association 28AMA 29 Claims Processing Report 21978 1AHIP Statement on American Medical Association 28AMA 29 Claims Processing Report 21978 2Mylan Announces Tentative FDA Approval for Generic Version of Antihypertensive Avalide 28R 29 Tablets 21975 1
...ngress of European Hematology,Association (EHA) -,...all/ --,Immunomedics, Inc. , a biopharmaceutical c... to treat cancer and other serious,diseases, today...s,of EHA in Vienna, Austria, showed positive respo... treated with a new,radioimmunotherapy (RAIT) usin...
...ational Reserve" May Also Affect,Alzheimer,s Risk ...e/ -- A new study,suggests that treating risk fact...od pressure and diabetes, may slow the progression...orted today at the,2nd Alzheimer,s Association Int... Washington, DC. , Two new studies presented at th...
Other Medicine Technology:Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study 2Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study 3Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study 4Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study 5Treating Heart Disease Risk Factors May Slow Alzheimer's Disease,Progression 2Treating Heart Disease Risk Factors May Slow Alzheimer's Disease,Progression 3Treating Heart Disease Risk Factors May Slow Alzheimer's Disease,Progression 4Treating Heart Disease Risk Factors May Slow Alzheimer's Disease,Progression 5Treating Heart Disease Risk Factors May Slow Alzheimer's Disease,Progression 6Treating Heart Disease Risk Factors May Slow Alzheimer's Disease,Progression 7
...tories is a national reference laboratory and a wo...nd development. ARUP offers an extensive test menu...nical and anatomic pathology. Owned by the Univers...re than half of the nation's university teaching h...
...tories is a national reference laboratory and a wo...nd development. ARUP offers an extensive test menu...nical and anatomic pathology. Owned by the Univers...re than half of the nation's university teaching h...
...tories is a national reference laboratory and a wo...nd development. ARUP offers an extensive test menu...nical and anatomic pathology. Owned by the Univers...re than half of the nation's university teaching h...
...tories is a national reference laboratory and a wo...nd development. ARUP offers an extensive test menu...nical and anatomic pathology. Owned by the Univers...re than half of the nation's university teaching h...
Medicine Products: